Alpha 2.0
Login Register
» Authors » I Novak-Hofer

I Novak-Hofer

Explore the profile of I Novak-Hofer including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 40
Citations 242
Followers 0
Related Specialties
Biochemistry
Oncology
Nuclear Medicine
Top 10 Co-Authors
P A Schubiger
I B Levitan
P Blauenstein
J R Lemos
H Amstutz
F Carrel
J J Morgenthaler
K Zimmermann
H P Amstutz
U Eppenberger
Published In
Eur J Nucl Med
Nucl Med Biol
Biochim Biophys Acta
Cancer Res
J Biol Chem
Affiliations
Soon will be listed here.
Recent Articles
1.
A comparison of targetting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients
Hoefnagel C, Rutgers M, Buitenhuis C, Smets L, Kraker J, Meli M, et al.
Eur J Nucl Med . 2014 Mar; 28(3):359-68. PMID: 24623005
Iodine-131 labelled anti L1-CAM antibody mAb chCE7 was compared with the effective neuroblastoma-seeking agent (131)I-labelled metaiodobenzylguanidine (MIBG) with regard to (a) its therapeutic efficacy in treating nude mice with neuroblastoma...
2.
Peptide linkers lead to modification of liver metabolism and improved tumor targeting of copper-67-labeled antibody fragments
Novak-Hofer I, Zimmermann K, Schubiger P
Cancer Biother Radiopharm . 2002 Jan; 16(6):469-81. PMID: 11789024
In order to determine if tumor/nontarget tissue ratios of 67Cu-labeled antibody fragments can be improved, modifying the DO3A copper chelate with tripeptide linkers was investigated. The peptide-linked chelates 1,4,7,10-tetraazacyclodecane-N,N',N",N"'-tetraacetate (DOTA)-triglycyl-L-p-isothiocyanato-phenylalanine...
3.
Cleavable linkers to enhance selectivity of antibody-targeted therapy of cancer
Kukis D, Novak-Hofer I, Denardo S
Cancer Biother Radiopharm . 2002 Jan; 16(6):457-67. PMID: 11789023
Radioimmunotherapy of cancer utilizes anti-tumor antibodies or antibody fragments conjugated to radionuclides to deliver radiation selectively to tumors. However, radiolabeled proteins deposit radioactivity in normal organs that metabolize or conserve...
4.
A comparison of targeting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients
Hoefnagel C, Rutgers M, Buitenhuis C, Smets L, de Kraker J, Meli M, et al.
Eur J Nucl Med . 2001 Apr; 28(3):359-68. PMID: 11315605
Iodine-131 labelled anti L1-CAM antibody mAb chCE7 was compared with the effective neuroblastoma-seeking agent 131I-labelled metaiodobenzylguanidine (MIBG) with regard to (a) its therapeutic efficacy in treating nude mice with neuroblastoma...
5.
IRIV-adjuvanted hepatitis A vaccine: in vivo absorption and biophysical characterization
Zurbriggen R, Novak-Hofer I, Seelig A, GLUCK R
Prog Lipid Res . 2000 Mar; 39(1):3-18. PMID: 10729605
Immunopotentiating reconstituted influenza virosomes (IRIV) are 150-nm proteoliposomes composed of influenza surface glycoproteins and a mixture of natural and synthetic phospholipids. Due to size, structure and composition of the IRIVs,...
6.
A triglycine linker improves tumor uptake and biodistributions of 67-Cu-labeled anti-neuroblastoma MAb chCE7 F(ab')2 fragments
Zimmermann K, Gianollini S, Schubiger P, Novak-Hofer I
Nucl Med Biol . 2000 Mar; 26(8):943-50. PMID: 10708309
The peptide-linked copper chelators CPTA-triglycyl-L-p-isothiocyanato-phenylalanine (CPTA-R1-NCS) as well as DOTA-triglycyl-L-p-isocyanato-phenylalanine (DOTA-R1-NCS) were synthesized and coupled to F(ab')2 fragments of the anti-neuroblastoma monoclonal antibody (MAb) chCE7. 67Cu-labeled conjugates were compared with...
7.
[76Br]Bromodeoxyuridine, a potential tracer for the measurement of cell proliferation by positron emission tomography, in vitro and in vivo studies in mice
Ryser J, Blauenstein P, Remy N, Weinreich R, Hasler P, Novak-Hofer I, et al.
Nucl Med Biol . 1999 Dec; 26(6):673-9. PMID: 10587106
5-Bromo-2'-deoxyuridine (BrUdR) labeled with 77Br and 76Br was compared with 5-iodo-2'-deoxyuridine (IUdR) labeled with 125I or 131I, first in vitro then in in vivo experiments in mice. The results showed...
8.
Anti-neuroblastoma antibody chCE7 binds to an isoform of L1-CAM present in renal carcinoma cells
Meli M, Carrel F, Waibel R, Amstutz H, Crompton N, Jaussi R, et al.
Int J Cancer . 1999 Sep; 83(3):401-8. PMID: 10495434
Immunoprecipitation after cell surface labeling of human neuroblastoma cells showed that the anti-neuroblastoma monoclonal antibody (mAb) chCE7 binds to a 200,000 M(r) cell surface protein. The protein was partially purified...
9.
Derivatives of 1,3,5-triamino-1,3,5-trideoxy-cis-inositol as versatile pentadentate ligands for protein labeling with Re-186/188. prelabeling, biodistribution, and X-ray structural studies
Kramer A, Alberto R, Egli A, Novak-Hofer I, Hegetschweiler K, Abram U, et al.
Bioconjug Chem . 1998 Nov; 9(6):691-702. PMID: 9815162
The pentadentate H3bhci [1,3,5-trideoxy-1, 3-bis((2-hydroxybenzyl)amino)-cis-inositol] and its bifunctionalized analogue H3bhci-glu-H [1,3,5-trideoxy-1, 3-bis((2-hydroxybenzyl)amino)-5-glutaramido-cis-inositol] were synthesized, and their coordination chemistry was investigated with inactive rhenium, with no carrier added Re-188 and with...
10.
Evaluation of radioiodinated and radiocopper labeled monovalent fragments of monoclonal antibody chCE7 for targeting of neuroblastoma
Carrel F, Amstutz H, Novak-Hofer I, Schubiger P
Nucl Med Biol . 1997 Aug; 24(6):539-46. PMID: 9316082
Monovalent fragments of antineuroblastoma antibody mAb chCE7 were evaluated for their in vitro and in vivo tumor cell binding properties. Single chain fragments were constructed from the variable region genes...